Bioavailability in Rats of Human Recombinant Tissue Plasminogen Activator After Subcutaneous and Intramuscular Injection

L J Garcia Frade; S Poole; S Hanley; L J Creighton; A D Curtis; P J Gaffney

doi:10.1055/s-0038-1661671

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1986; 56(03): 299-301
DOI: 10.1055/s-0038-1661671

Original Article

Schattauer GmbH Stuttgart

Bioavailability in Rats of Human Recombinant Tissue Plasminogen Activator After Subcutaneous and Intramuscular Injection

L J Garcia Frade

The National Institute for Biological Standards and Control, Hampstead, London, England

,

S Poole

The National Institute for Biological Standards and Control, Hampstead, London, England

,

S Hanley

The National Institute for Biological Standards and Control, Hampstead, London, England

,

L J Creighton

The National Institute for Biological Standards and Control, Hampstead, London, England

,

A D Curtis

The National Institute for Biological Standards and Control, Hampstead, London, England

,

P J Gaffney

The National Institute for Biological Standards and Control, Hampstead, London, England

› Author Affiliations

Abstract

PDF Download

Summary

The bioavailability of human recombinant tissue plasminogen activator (rt-PA) in rats was measured after subcutaneous (s.c.) and intramuscular (i.m.) injection. Rt-PA was absorbed after both i.m. and s.c. injection, giving peak plasma concentrations within 30 min and 1 h, respectively, with detectable concentrations up to 6 h. These peak values of bioavailable t-PA were obtained in a functional fibrin plate assay of euglobulin precipitates and expressed as +88% and +243% (for s.c. and i.m. routes respectively) above basal rat fibrinolytic activity. Prior injection of rt-PA, s.c. or i.m., significantly reduced the weights of thrombi induced in the inferior vena cava after injection.

Keywords

Recombinant tissue plasminogen activator - Subcutaneous - Intramuscular - Rat - Thrombus

PDF (637 kb)

References

References
1 Gaffney PJ. Fibrinolysis. In: Haemostasis and Thrombosis, 2nd ed Bloom AL, Thomas DP. (eds). Churchill Livingstone; Oxford: 1986. (in press)
2 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
3 Verhejen JH, Chang TG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1983; 51: 392-395
4 Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
5 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
6 Gaffney PJ, Creighton L, Pring JB, Mahmoud M. Tissue plasminogen activator (t-PA) and its specific inhibitor (PAI). A model of functional expedience. Thromb Haemostas 1985; 54: 270
7 Brommer EJ P. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis, inefficiency of activators added afterwards. Thromb Res 1984; 34: 109-115
8 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue type plasminogen activator for cDNA in E. Coli. Nature 1983; 301: 214-221
9 The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial. N Engl J Med 1985; 312: 932-936
10 Report from the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 1: 842-847
11 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
12 Reyers I, Mussoni L, Donati MB, De Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980; 18: 669-674
13 Mahmoud M, Gaffney PJ. Bioimmunoassay (BIA) of tissue plasminogen activator (t-PA) and its specific inhibitor (t-PA/INH). Thromb Haemostas 1985; 53: 356-359
14 Haverkate F, Traas DW. Dose response curves in the fibrin plate assay. Fibrinolytic activity of proteases. Thrombos Diathes Haemorrh 1974; 32: 356-365
15 Nilsson I-M, Olow B. Fibrinolysis induced by streptokinase in man. Acta Chir Scand 1962; 123: 247-266
16 Rijken DC, Van Hinsbergh VW M, Sens EH C. Quantitation of tissue type plasminogen activator in human endothelial cultures by use of an enzyme immunoassay. Thromb Res 1984; 33: 145-153
17 Gaffney PJ, Curtis AD. A collaborative study of a proposed International Standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
18 Finney DJ. Statistical Method in Biological Assay. 3rd edition, Griffin, London 1978
19 Bradley JV. Distribution-Free Statistical Tests. Prentice-Hall Inc.; New Jersey: 1968: 104-111
20 Sobel BE, Fields LE, Robison AK, Fox KA A, Sarnoff SJ. Coronary thrombolysis with facilitated adsorption of intramuscularly injected tissue-type plasminogen activator. Proc Nat Acad Sci USA 1985; 82: 4258-4262
21 Poole S. Cardiovascular responses of rats to intrahypothalamic injection of carbachol and noradrenaline. Br J Pharmac 1983; 79: 693-700
22 Blake CA, Sawyer CH. Ovulation blocking actions of urethane in the rat. Endocrinology 1972; 91: 87-94
23 Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemostas 1981; 46: 561-565